Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Oncology Market Leaders – Analyses and Outlook – 2010-2025
Market Study
Published: January 2010
Pages: For full details, please email keithw@cmsinfo.com
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 1499.00 Buy Now!
Research from: Visiongain
Sector: Prescription Medicines
how will this crucial pharma market develop? Our new report explains
Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows.
The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions.
This report examines commercial prospects for the following therapy types in particular:
• Traditional cytotoxic chemotherapies
• Hormone therapies
• Immunotherapies
• Novel antineoplastic drugs.
What new agents are likely to enter the cancer treatments market from 2010 onwards? Do they hold the potential to dominate this market area? What issues are shaping the anti-cancer market? Where will the best commercial opportunities lie from 2010 onwards? What are the most-crucial drivers and restraints in the cancer treatments sector? This report will provide you with the information that you need to understand current trends and future commercial possibilities there. In particular, Oncology Market Leaders – Analyses and Outlook – 2010-2025 analyses sales prospects for the following products:
• Avastin
• MabThera
• Herceptin
• Glivec/Gleevec
• Taxotere
• Eloxatin
• Arimidex
• Gemzar
• Erbitux
• Alimta
Also included is analysis of the leading companies in the anti-cancer drug sector. There, we discuss major portfolio and pipeline products, as well as their future therapeutic and commercial prospects.
Comprehensive analysis of the oncology market sector
Oncology Market Leaders – Analyses and Outlook – 2010-2025 examines the cancer treatments market critically, through a comprehensive review of information sources. We harness both primary and secondary research. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analyses. The report contains over 140 tables and figures, as well as three full interviews with relevant authorities. You will discover a comprehensive market- and industry-centred study, one with detailed analyses and informed opinion to benefit your work.
Why you should buy Oncology Market Leaders – Analyses and Outlook – 2010-2025
This report will provide you with the following benefits, in particular:
• You will assess the current market for pharmacological cancer treatments
• You will review the overall anti-cancer drug market, including our global sales forecast for 2010 to 2025, and a geographical breakdown of relevant sales revenues
• You will receive our sales forecasts for the leading therapy classes from 2010 to 2025, with detailed discussions
• You will receive our sales forecasts for the leading products in this market from 2010 to 2025, with detailed discussions of market potential and competition
• You will obtain informed analyses of the leading companies’ portfolios, pipelines and commercial prospects in the sector
• You will examine commercial drivers and restraints in depth, exploring their significance from 2010 onwards
• You will discover the most-exciting R&D pipeline developments in the sector, with informed commentary
• You will read expert opinions from our original survey of the sector, with contributions from industry and academia
• You will view discussion of under-met needs in cancer treatment.
You can obtain this report today
Nobody with an interest in the anti-cancer drug market should overlook this new study. We predict that total revenues will increase there, with the anti-cancer drug segment contributing increasingly to the success of the pharmaceutical and biotechnology industries. With expanding patient populations, technological advances and strong R&D pipelines, the anti-cancer drug sector holds particularly high commercial potential. Do you want to harness those opportunities? You can stay ahead by ordering this report today.
Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows.
The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions.
This report examines commercial prospects for the following therapy types in particular:
• Traditional cytotoxic chemotherapies
• Hormone therapies
• Immunotherapies
• Novel antineoplastic drugs.
What new agents are likely to enter the cancer treatments market from 2010 onwards? Do they hold the potential to dominate this market area? What issues are shaping the anti-cancer market? Where will the best commercial opportunities lie from 2010 onwards? What are the most-crucial drivers and restraints in the cancer treatments sector? This report will provide you with the information that you need to understand current trends and future commercial possibilities there. In particular, Oncology Market Leaders – Analyses and Outlook – 2010-2025 analyses sales prospects for the following products:
• Avastin
• MabThera
• Herceptin
• Glivec/Gleevec
• Taxotere
• Eloxatin
• Arimidex
• Gemzar
• Erbitux
• Alimta
Also included is analysis of the leading companies in the anti-cancer drug sector. There, we discuss major portfolio and pipeline products, as well as their future therapeutic and commercial prospects.
Comprehensive analysis of the oncology market sector
Oncology Market Leaders – Analyses and Outlook – 2010-2025 examines the cancer treatments market critically, through a comprehensive review of information sources. We harness both primary and secondary research. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analyses. The report contains over 140 tables and figures, as well as three full interviews with relevant authorities. You will discover a comprehensive market- and industry-centred study, one with detailed analyses and informed opinion to benefit your work.
Why you should buy Oncology Market Leaders – Analyses and Outlook – 2010-2025
This report will provide you with the following benefits, in particular:
• You will assess the current market for pharmacological cancer treatments
• You will review the overall anti-cancer drug market, including our global sales forecast for 2010 to 2025, and a geographical breakdown of relevant sales revenues
• You will receive our sales forecasts for the leading therapy classes from 2010 to 2025, with detailed discussions
• You will receive our sales forecasts for the leading products in this market from 2010 to 2025, with detailed discussions of market potential and competition
• You will obtain informed analyses of the leading companies’ portfolios, pipelines and commercial prospects in the sector
• You will examine commercial drivers and restraints in depth, exploring their significance from 2010 onwards
• You will discover the most-exciting R&D pipeline developments in the sector, with informed commentary
• You will read expert opinions from our original survey of the sector, with contributions from industry and academia
• You will view discussion of under-met needs in cancer treatment.
You can obtain this report today
Nobody with an interest in the anti-cancer drug market should overlook this new study. We predict that total revenues will increase there, with the anti-cancer drug segment contributing increasingly to the success of the pharmaceutical and biotechnology industries. With expanding patient populations, technological advances and strong R&D pipelines, the anti-cancer drug sector holds particularly high commercial potential. Do you want to harness those opportunities? You can stay ahead by ordering this report today.
Companies Listed
Abraxis BioScience Inc.
Access Pharmaceuticals Inc.
Actavis
Almac Group Ltd
American Cancer Society
Apotex
AstraZeneca
Bayer Healthcare
Biogen Idec
BiPar Science Inc.
Bristol-Myers Squibb
British National Formulary
Cancer Research UK
Cell Therapeutics Inc.
Committee for Medicinal Products for Human Use (CHMP)
Chugai Pharmaceuticals
CytImmune Sciences
Dendreon Corporation
Dr. Reddy’s Laboratories
Eli Lilly
European Medicines Agency (EMEA)
Food and Drug Administration (FDA)
Genentech
Genta Inc.
GlaxoSmithKline
Hospira Inc.
ImClone Systems
International Agency for Research on Cancer (IARC)
Johnson & Johnson
Merck & Co
Merck KGaA
Merck Serono
National Cancer Institute (NCI)
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
National Institutes of Health (NIH)
Novartis
Pfizer
Regeneron Pharmaceuticals Inc.
Roche
Sandoz
Sanofi-Aventis
Schering Plough
Serono
Stada Arzneimittel AG
Teva Pharmaceutical Industries
US Preventive Services Task Force (USPSTF)
Ventana Medical Systems
Vernalis
World Health Organisation (WHO)
Wyeth Pharmaceuticals
Yeda Research and Development Company Ltd.
Zenyaku Kogyo Co. Ltd.